From Financial Modeling Prep: 2025-04-24 02:49:00

Novo Nordisk’s sales of Wegovy have consistently exceeded expectations since 2021, but recent U.S. prescription data and competition from Eli Lilly’s Zepbound may signal a slowdown. Analysts warn Novo might revise its 2025 growth outlook after Q1 results on May 7.

Weekly Wegovy prescriptions in the U.S. have stalled since mid-February, despite increased shipments, according to IQVIA data. This plateau raises concerns about market penetration and patient retention rates.

Eli Lilly’s Zepbound has surged ahead of Wegovy with 128,000 more scripts in a week ending April 11. Increased switching and sampling programs could further impact Novo Nordisk’s volume growth.

Investors are keeping a close eye on Novo Nordisk’s revenue trajectory amidst intensifying competition and potential trade-war headwinds. Monitoring key metrics like net sales growth and EBITDA margins can provide insights into future guidance updates.



Read more at Financial Modeling Prep:: Novo Nordisk Faces Guidance Risks as Wegovy Prescr…